MAXHEALTH vs TATACONSUM: Stock Comparison
TATA CONSUMER PRODUCT is the larger company by market capitalisation. MAX HEALTHCARE INS shows a lower P/E, a higher ROE and a higher ROCE, while TATA CONSUMER PRODUCT shows a higher dividend yield and faster revenue growth. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
MAXHEALTH leads 5; TATACONSUM leads 5 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | MAXHEALTH | TATACONSUM |
|---|---|---|
| Sector | Healthcare | Fast Moving Consumer Goods |
| Industry | Hospital | Tea & Coffee |
Price
| Metric | MAXHEALTH | TATACONSUM |
|---|---|---|
| Live Price | ₹815 | ₹963.9 |
| Day Change | -0.24% | 0.43% |
| Volume | 36.27 L | 14.75 L |
| 52-Week High | ₹1,221.9 | ₹1,282.7 |
| 52-Week Low | ₹797 | ₹945 |
| Distance from 52W High | -33.3% | -24.85% |
Valuation
| Metric | MAXHEALTH | TATACONSUM |
|---|---|---|
| Market Cap | ₹79,519 Cr | ₹95,011 Cr |
| P/E Ratio | 54.54x | 58.11x |
| P/B Ratio | 7.4x | 4.36x |
| EPS | ₹3.32 | ₹16.52 |
| Book Value | ₹110.42 | ₹220.17 |
| Dividend Yield | 0.25% | 1.03% |
Growth
| Metric | MAXHEALTH | TATACONSUM |
|---|---|---|
| Revenue Growth (TTM YoY) | 12.2% | 17.9% |
| EPS Growth (TTM YoY) | 7.3% | 21.5% |
| Qtr Sales Growth | 0% | 0% |
| Qtr Profit Growth | 0% | 0% |
Profitability & Leverage
| Metric | MAXHEALTH | TATACONSUM |
|---|---|---|
| ROE | 8.02% | 6.67% |
| ROCE | 8.15% | 7.91% |
| Net Margin | 17.23% | 7.44% |
| Operating Margin | 33.54% | 11.38% |
| Debt to Equity | 0.09x | 0.09x |
Shareholding
As of Sep 2026 • change vs previous quarter| Metric | MAXHEALTH | TATACONSUM |
|---|---|---|
| Promoter Holding | 23.71% | 33.83% |
| FII Holding | 40.52%▼ 1.26 pp | 20.08%▼ 0.71 pp |
| DII Holding | 31%▲ 1.04 pp | 25.01%▲ 0.82 pp |
| Public Holding | 4.76%▲ 0.2 pp | 21.07%▼ 0.11 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: MAX HEALTHCARE INS and TATA CONSUMER PRODUCT.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.